Background This study was designed to explore the therapeutic potential of suppressing MAP kinase and PI3K/Akt pathways and histone deacetylase (HDAC) to induce the expression of sodium/iodide symporter (NIS) and radioiodine uptake in non-thyroid cancer cells. Methods We tested the effects of the MEK inhibitor RDEA119, the Akt inhibitor perifosine, and the HDAC inhibitor SAHA on NIS expression in thirteen human cancer cell lines derived from melanoma, hepatic carcinoma, gastric carcinoma, colon carcinoma, breast carcinoma, and brain cancers. We also examined radioiodine uptake and histone acetylation at the NIS promoter in selected cells. Results Overall, the three inhibitors could induce NIS expression, to various extents, in melanoma and all the epithelial carcinoma-derived cells but not in brain cancer-derived cells. SAHA was most effective and its effect could be significantly enhanced by RDEA119 and perifosine. The expression of NIS, at both mRNA and protein levels, was most robust in the melanoma cell M14, hepatic carcinoma cell HepG2, and the gastric carcinoma cell MKN-7 cell. Radioiodine uptake was correspondingly induced, accompanied by robust increase in histone acetylation at the NIS promoter, in these cells when treated with the three inhibitors. Conclusions This is the first demonstration that simultaneously suppressing the MAP kinase and PI3K/Akt pathways and HDAC could induce robust NIS expression and radioiodine uptake in certain non-thyroid human cancer cells, providing novel therapeutic implications for adjunct radioiodine treatment of these cancers.
References
[1]
Jhiang SM (2000) Regulation of sodium/iodide symporter. Rev Endocr Metab Disord 1: 205–15.
[2]
Spitzweg C, Morris JC (2002) The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf) 57: 559–74.
[3]
Baker CH, Morris JC (2004) The sodium-iodide symporter. Curr Drug Targets Immune Endocr Metabol Disord 4: 167–74.
[4]
Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, et al. (2010) The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets 10: 242–67.
[5]
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, et al. (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154: 787–803.
[6]
Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167–214.
[7]
Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM (1997) Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 138: 3555–8.
[8]
Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, et al. (1998) Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 83: 2493–6.
[9]
Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, et al. (1998) Na+/I？ symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 83: 4102–6.
[10]
Park HJ, Kim JY, Park KY, Gong G, Hong SJ, et al. (2000) Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas. Thyroid 10: 211–7.
[11]
Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, et al. (2001) Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(？) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86: 3430–5.
[12]
Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, et al. (2002) Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132: 984–90.
[13]
Hou P, Bojdani E, Xing M (2010) Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab 95: 820–8.
[14]
Cho JY (2002) A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy. Curr Gene Ther 2: 393–402.
[15]
Jhiang SM, Cho JY, Ryu KY, DeYoung BR, Smanik PA, et al. (1998) An immunohistochemical study of Na+/I？ symporter in human thyroid tissues and salivary gland tissues. Endocrinology 139: 4416–9.
[16]
Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, et al. (1999) Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab 84: 4178–84.
[17]
Spitzweg C, Dutton CM, Castro MR, Bergert ER, Goellner JR, et al. (2001) Expression of the sodium iodide symporter in human kidney. Kidney Int 59: 1013–23.
[18]
Morgenstern KE, Vadysirisack DD, Zhang Z, Cahill KV, Foster JA, et al. (2005) Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients. Ophthal Plast Reconstr Surg 21: 337–44.
[19]
Kang do Y, Lee HW, Choi PJ, Lee KE, Roh MS (2009) Sodium/iodide symporter expression in primary lung cancer and comparison with glucose transporter 1 expression. Pathol Int 59: 73–9.
[20]
Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, et al. (2000) The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 6: 871–8.
[21]
Hou P, Liu D, Ji M, Liu Z, Engles JM, et al. (2009) Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications. PLoS One 4: e6200.
[22]
MacDonald VE, Howe LJ (2009) Histone acetylation: where to go and how to get there. Epigenetics 4: 139–43.
[23]
Li W, Venkataraman GM, Ain KB (2007) Protein synthesis inhibitors, in synergy with 5-azacytidine, restore sodium/iodide symporter gene expression in human thyroid adenoma cell line, KAK-1, suggesting trans-active transcriptional repressor. J Clin Endocrinol Metab 92: 1080–7.
[24]
Greenler DP, Klein HA (1984) The scope of false-positive iodine-131 images for thyroid cancer. Clin Nucl Med 14: 111–117.
[25]
Rosenbaum RC, Johnston GS, Valente WA (1988) Frequency of hepatic visualization during-131 imaging of metastatic thyroid carcinoma. Clin Nucl Med 13: 657–660.
[26]
Bakheet SM, Hammami M (1994) Patterns of radioiodine uptake by the lactating breast. Eur J Nucl Med 21: 604–608.
[27]
McDougall IR (1995) Whole-body scintigraphy with radioiodine-131. A comprehensive list of false-positives with some examples. Clin Nucl Med 20: 869–875.
[28]
Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, et al. (2005) Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 146: 3967–74.
[29]
Kogai T, Schultz JJ, Johnson LS, Huang M, Brent GA (2000) Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci U S A 97: 8519–24.
[30]
Wong KK, Engelman JA, Cantley LC (2010) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20: 87–90.
Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, et al. (2011) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. Oncotarget 2: 135–64.
[33]
Kim HJ, Bae SC (2011) Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 3: 166–79.
[34]
Carafa V, Nebbioso A, Altucci L (2011) Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Pat Anticancer Drug Discov 6: 131–45.
[35]
Slominski A, Wortsman J, Kohn L, Ain KB, Venkataraman GM, et al. (2002) Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. J Invest Dermatol 119: 1449–55.
[36]
Ellerhorst JA, Sendi-Naderi A, Johnson MK, Cooke CP, Dang SM, et al. (2006) Human melanoma cells express functional receptors for thyroid-stimulating hormone. Endocr Relat Cancer 13: 1269–77.
[37]
Liu Z, Liu D, Bojdani E, El-Naggar AK, Vasko V, et al. (2010) IQGAP1 plays an important role in the invasiveness of thyroid cancer. Clin Cancer Res 16: 6009–18.
